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 Introduction 
 Lung epithelial cells form a tight functional barrier 
which is essential for the maintenance of normal lung 
function throughout life  [1] . The alveolar epithelium is 
composed of alveolar epithelial type I (ATI) and type II 
(ATII) cells. ATII cells are cuboidal secretory cells main-
ly responsible for surfactant secretion, thereby reducing 
surface tension  [2] . In addition, ATII cells have been im-
plicated in lung defense mechanisms due to cytokine re-
lease and antioxidant production. ATII cells supposedly 
serve as progenitors, initiating the restoration of alveolar 
epithelium in the adult lung by either giving rise to new 
ATII cells or differentiating into ATI cells  [3] . While less-
er in number, ATI cells cover over 95% of the alveolar 
surface area, thereby providing the basis for gas exchange 
 [4] . Alveolar epithelial cells exhibit a high degree of plas-
ticity and are involved in injury, repair, and transforma-
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 Abstract 
 Lung epithelial cells exhibit a high degree of plasticity. Al-
terations to lung epithelial cell function are critically involved 
in several chronic lung diseases such as pulmonary fibrosis. 
Pulmonary fibrosis is characterized by repetitive injury and 
subsequent impaired repair of epithelial cells, which leads to 
aberrant growth factor activation and fibroblast accumula-
tion. Increased proliferation and hyper- and metaplasia of 
epithelial cells upon injury have also been observed in pul-
monary fibrosis; this epithelial cell activation might repre-
sent the basis for lung cancer development. Indeed, several 
studies have provided histopathological evidence of an in-
creased incidence of lung cancer in pulmonary fibrosis. The 
mechanisms involved in the development of cancer in pul-
monary fibrosis, however, remain poorly understood. This 
review highlights recently uncovered molecular mecha-
nisms shared between lung cancer and fibrosis, which ex-
tend the current evidence of a common trait of cancer and 
fibrosis, as provided by histopathological observations. 
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tion processes of the lung. Alveolar epithelial cell injury 
and impaired repair have been linked to several chronic 
lung diseases such as pulmonary fibrosis  [5] .
 Idiopathic pulmonary fibrosis (IPF) represents one of 
the most common and progressive fibrotic disorders; it is 
characterized by repetitive injury and subsequent im-
paired repair of alveolar epithelial cells. This leads to 
 aberrant  growth  factor activation and perpetuation of 
the fibrotic transformation and aggregation of activated 
myofibroblasts (fibroblast foci), which promote excessive 
extracellular matrix deposition  [6, 7] . Hyperplastic pro-
liferating alveolar epithelial cells are frequently found in 
IPF, and alveolar epithelial cell proliferation may be in-
volved in impaired repair mechanisms  [8–10] .
 These observations strongly suggest that fibrotic epi-
thelial cells may serve as a possible origin of carcinoma 
development. Other histological cell atypies that have 
been observed in IPF include bronchiolization as well as 
squamous and bronchial basal cell metaplasia that are 
similar to premalignant lesions in the bronchial epithe-
lium  [11, 12] . Along this line, Chilosi et al.  [8] reported 
abnormal proliferation of bronchial epithelial cells in IPF 
but not in other interstitial pneumonias such as acute or 
nonspecific pneumonias.
 Several studies have provided histopathological evi-
dence of an increased incidence of lung cancer in IPF. 
Hironaka et al.  [13] found that squamous metaplasia oc-
curred more frequently in patients with usual interstitial 
pneumonia (the histopathological correlate of IPF) and 
lung cancer compared with usual interstitial pneumonia 
without lung cancer. Epidemiological studies have re-
ported a prevalence of lung cancer in up to 30% of pul-
monary fibrosis cases  [14] . Further, the role of cigarette 
smoking as an established risk factor for both IPF and 
lung cancer has been investigated in several studies  [11, 
15, 16] . It has been reported that IPF patients with lung 
cancer exhibit a significantly higher smoking index than 
do IPF patients without lung cancer. Interestingly, Hub-
bard et al.  [17] provided evidence that the increased prev-
alence of lung cancer in IPF is independent of smoking. 
In the analyzed cohort, the incidence of lung cancer was 
significantly increased in IPF patients even after adjust-
ment for previous smoking history.
 Of further interest is the histological localization of 
tumors within the fibrotic lung. Most cancer cases have 
been identified in the lung periphery and lower lobes, 
closely located to fibrotic changes which predominantly 
occur within these areas  [11, 12] . Histologically, different 
subtypes of lung cancer such as small cell carcinoma, ad-
enocarcinoma, or squamous cell carcinoma have been re-
ported often, but not exclusively, in nontypical locations 
in the lung periphery  [18, 19] .
 The real incidence and occurrence of lung cancer in 
pulmonary fibrosis, however, may very likely be underes-
timated for several reasons: (1) the nontypical localization 
of tumors in the lower lobes, which may hamper its radio-
logical detection in pulmonary fibrosis, particularly since 
previous studies have only been performed upon autopsy, 
(2) the current reassessment of the classification of idio-
pathic interstitial pneumonias, which limits retrospective 
analysis due to differences in diagnostic accuracy and no-
menclature, and (3) the progressive course of IPF with an 
overall survival of 2–4 years after diagnosis and no proven 
therapeutic option, which may lead to the fact that IPF pa-
tients may die before lung cancer develops or is detected.
 Clearly, the mechanisms involved in the development 
of  cancer  remain  poorly  understood.   Recent   advances 
in our understanding of the molecular mechanisms in-
volved in pulmonary fibrosis have complemented the his-
topathological evidence and provided a deeper insight 
into the possible pathomechanisms involved in lung can-
cer development in patients with pulmonary fibrosis. The 
aim of this review, therefore, is to highlight these novel 
findings linking pulmonary fibrosis with lung cancer.
 Epithelial Cell Phenotype in Pulmonary Fibrosis 
 The findings that lung epithelial cells from fibrotic 
lungs appear hyper- and metaplastic in IPF  [8, 20, 21] has 
been further examined by ultrastructural studies that re-
vealed the existence of proliferative alveolar epithelial cells 
immediately adjacent to injured and apoptotic epithelial 
cells  [22–24] . The simultaneous occurrence of epithelial 
apoptosis, hyperplasia, and proliferation is also a consis-
tent finding in experimental lung fibrosis  [25, 26] , suggest-
ing that an ongoing injury repair process in fi brosis rep-
resents the basis for lung cancer development. These re-
sults have been further corroborated on the cellular level. 
Primary alveolar epithelial cells isolated from fibrotic 
lungs exhibited an increased proliferative capacity and en-
hanced gene expression of proliferative mediators  [27] .
 Importantly, several genes and pathways which have 
been assigned an oncogenic role, such as the WNT/  -
catenin signaling pathway, have been found to be altered 
in these cells. In addition, fibrotic primary alveolar epi-
thelial cells have been shown to exhibit an enhanced mi-
gratory ability and may undergo epithelial-to-mesenchy-
mal transition (EMT), a mechanism which further links 
fibrosis and cancer development  [27–29] ( fig. 1 ).
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 Epithelial-to-Mesenchymal Transition 
 EMT is defined as the reversible phenotypic alteration 
of an epithelial into a fibroblast-like cell and has been de-
scribed in the process of embryonic development, can-
cerogenesis, and organ fibrosis  [30, 31] . The EMT process 
is characterized by changes in cell polarity, remodeling of 
cell-cell and cell-matrix adhesion contacts, loss of epithe-
lial cell markers, induction of mesenchymal gene expres-
sion, and reorganization of the actin cytoskeleton with a 
subsequent enhanced ability for cell migration  [31, 32] .
 In lung cancer, EMT has been described in the context 
of cancer invasion and metastasis, and it has been pro-
posed to be a survival strategy for cells to avoid induction 
of apoptosis by drug treatment  [33, 34] . In vivo evidence, 
however, documenting that EMT is involved in lung can-
cer progression is still missing. In pulmonary fibrosis, 
epithelial cells, via the process of EMT, possibly serve as 
a source for the increased (myo-)fibroblast pool  [35] . Re-
cent studies have demonstrated evidence of EMT in IPF 
tissue specimens as well as in allografts after lung trans-
plantation  [36] . Colocalization of epithelial and mesen-
chymal marker expression in hyperplastic alveolar epi-
thelial cells in lung tissue from IPF patients suggested 
that EMT significantly contributes to IPF pathogenesis 
 [28] . One of the main inducers of EMT is transforming 
growth factor (TGF)-  , a cytokine also implicated in 
cancer metastasis  [37] . It has been demonstrated that 
TGF-  induces EMT in alveolar epithelial cells in vitro 
and in vivo  [28, 29, 38] . Upon exposure to TGF-  , alveo-
lar epithelial cells gain mesenchymal marker gene ex-
pression while loosing epithelial markers, indicative of 
EMT  [39] . Recently, TGF-  -induced EMT was also dem-
onstrated in vivo in a triple transgenic mouse model  [29] .
 Enhanced cellular migration is closely linked with 
EMT  [31] . Matrix metalloproteinases (MMP) are critical-
ly involved in these processes by cleaving extracellular 
matrix proteins and activating growth factor signaling. 
Altered MMP expression has been reported in wound 
healing, organ fibrosis, and cancer development  [40, 41] . 
Matrilysin (MMP7) is expressed and secreted by lung ep-
ithelial cells and has been found to be upregulated in hu-
 Fig. 1. Potential mechanisms involved in 
lung cancer development in pulmonary 
 fibrosis. Alterations in the epithelial cell 
phenotype, such as dysplasia, prolifera-
tion, or EMT, may be driven by oncogenic 
signal pathways that are aberrantly acti-
vated in pulmonary fibrosis.
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man and experimental fibrosis  [42] . MMP7 is known to 
be a WNT/  -catenin target gene and has further been 
suggested to promote invasiveness in lung cancer  [43] . 
How MMP expression may foster cancer development in 
fibrosis has been reported in transgenic animal models in 
which overexpression of MMP3 or membrane type-1 
(MT1)-MMP led to increased collagen deposition and fi-
brosis followed by tumorigenesis in the breast  [44, 45] . 
Similar  mechanisms may be relevant for the lung but 
have not been reported thus far.
 In summary, the ability of lung epithelial cells to ex-
press MMP, migrate, and undergo EMT warrants future 
studies to determine the temporal and spatial role that 
EMT may play in the development of lung cancer within 
pulmonary fibrosis.
 Oncogenic Signaling Pathways 
 Cancer develops via a multistep process involving tu-
mor suppressors as well as oncogenes that trigger the 
transition of normal epithelial cells to metaplastic and 
subsequently carcinoma cells  [46] . This paragraph focus-
es on tumor suppressors as well as oncogenes that have 
been implicated in pulmonary fibrosis and cancer alike.
 First, the well-known tumor suppressor protein p53 is 
altered in squamous metaplasia and dysplastic bronchial 
and alveolar epithelium in patients with IPF  [47, 48] . It 
has been demonstrated that chronic epithelial cell injury 
coincides with the upregulation of p53 and p21 and sub-
sequent (impaired) repair may lead to point mutations 
within  the p53 gene, resulting in a loss of function  [47, 
49] . This may represent an early trigger of epithelial cell 
transformation and tumorigenesis. In addition, expres-
sion  of   a   truncated   isoform   of   p63   (deltaN-p63)   has 
been reported at sites of epithelial hyperplasia, squamous 
metaplasia, bronchiolization, and abnormal p53 nuclear 
accumulation in IPF  [8] .
 Aberrant expression of developmentally active signal-
ing pathways is a common and well-investigated feature 
of cancer, but this mechanism has been largely underap-
preciated in nonmalignant diseases. Recently, these on-
cogenic pathways have been uncovered in the develop-
ment and progression of pulmonary fibrosis  [50, 51] . One 
of the most prominent pathways is the highly conserved 
WNT/  -catenin signaling pathway, which has been 
found to be aberrantly activated in chronic fibrotic lung 
disease  [52, 53] . The WNT/  -catenin signaling pathway 
constitutes a large family of secreted glycoproteins that 
signal via a variety of membrane-bound receptors. In 
short, in the presence of WNT ligands, the membrane 
receptors frizzled (FZD) and low-density lipoprotein re-
ceptor-related protein (LRP) 5 or 6 are activated upon 
WNT binding. WNT ligand binding to FZD and LRP 
leads to the phosphorylation of LRP6 by glycogen syn-
thase kinase (GSK)-3  and casein kinase   in its cyto-
plasmic region, which leads to the recruitment of the cy-
tosolic proteins dishevelled (DVL) 1–3 and axin. Subse-
quently,   -catenin phosphorylation is inhibited and its 
degradation attenuated. Accumulated   -catenin under-
goes nuclear translocation and regulates target gene ex-
pression via interaction with members of the T-cell- 
specific transcription factor/lymphoid enhancer-binding 
factor (TCF/LEF) family  [54] .
 Chilosi et al.  [53] reported nuclear localization of   -
catenin  in  the  hyperplastic  alveolar epithelium, as well 
as interstitium in IPF, indicative of activated WNT/
  -catenin signaling. In addition, it has been recently 
 demonstrated that several components of the canonical 
WNT/  -catenin signaling pathway are overexpressed 
in human    IPF    [52]   as   well   as   in   experimental   lung   fi-
brosis  [27] . Interestingly, canonical WNT/  -catenin sig-
naling components (including WNT ligands,   -catenin, 
or GSK-3  )    localized    mainly    to    the    bronchial   and   al-
veolar epithelium. Increased activity of the WNT/  -
catenin pathway in IPF was documented by increased 
phosphorylation of LRP6 and GSK-3  . In addition, sev-
eral WNT target genes such as MMP7 or fibronectin are 
differentially expressed in IPF,  [42] . Activation of ca-
nonical WNT/  -catenin signaling has been further 
demonstrated in experimental lung fibrosis in vivo  [27, 
55, 56] . A whole genome microarray screen from pri-
mary alveolar epithelial cells isolated from fibrotic 
mouse lungs revealed an ‘oncogene signature’ including 
WNT components and target genes but also from other 
pathways  [27] . In particular, increased expression of the 
WNT target gene WNT-inducible signaling pathway 
protein (WISP) 1 has been found in hyperplastic prolif-
erating alveolar epithelial cells  [57] . WISP1 led to en-
hanced epithelial proliferation and migration as well as 
EMT. WNT ligands themselves lead to an increased 
proliferation of bronchial and alveolar epithelial cells in 
vitro. The impact of WNT/  -catenin signaling as a reg-
ulator of EMT has been demonstrated by the direct par-
ticipation of   -catenin in these processes  [58, 59] as well 
as by induction of EMT by Wnt ligands in vitro  [60] . Al-
though in vivo evidence is still missing, the aforemen-
tioned data highlight the WNT/  -catenin pathway and 
its target gene WISP1 as possible mediators of lung can-
cer development in pulmonary fibrosis ( fig. 1 ). Indeed, 
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WISP1 alterations have been reported in lung cancer 
specimens  [61–63] . In addition, increased activity of the 
upstream WNT/  -catenin pathway has also been re-
ported.  Several  studies  have  reported   increased   nucle-
ar   -catenin staining in several lung tumor samples. 
Changes in the expression of several Wnt components 
(such as Wnt1, Wnt2, and Dvl3) have been reported  in 
non-small  cell lung carcinoma and associat ed with en-
hanced cell growth and/or resistance to apopto tic ther-
apies  [64] . Additional studies have demonstrated that 
Wnt regulators are transcriptionally silenced in non-
small cell lung carcinoma, thereby promoting tumor 
growth  [65, 66] .
 Altogether, these studies represent profound evidence 
that links active WNT/  -catenin signaling with alveolar 
and bronchial epithelial cell injury and repair. Future 
studies are needed to further elucidate the effects and 
mechanisms of active WNT/  -catenin signaling and to 
analyze whether this pathway plays a causative role in 
lung cancer development in pulmonary fibrosis.
 Conclusion 
 Pulmonary fibrosis is characterized by repetitive cy-
cles of epithelial cell injury followed by impaired epithe-
lial cell repair. Phenotypic alterations, such as hyper- and 
metaplasia, have been described in IPF and strongly sug-
gest that fibrotic epithelial cells may be able to further 
transform, thereby representing a possible origin of car-
cinoma development. Although an increased incidence 
of lung cancer in pulmonary fibrosis has been reported, 
this field warrants further investigation. Recent advances 
in our understanding of the molecular mechanisms of 
pulmonary fibrosis have complemented the histopatho-
logical evidence. Processes such as EMT or (re-)activa-
tion of oncogenic pathways have been implicated in pul-
monary fibrosis development, in particular in alveolar 
epithelial cell injury und repair mechanisms. These nov-
el findings provide further evidence on the molecular 
and cellular level of a close link between pulmonary fi-
brosis and lung cancer. 
 References 
 1 Matthay MA, Robriquet L, Fang X: Alveolar 
epithelium: role in lung fluid balance and 
acute lung injury. Proc Am Thorac Soc 2005; 
 2: 206–213. 
 2 Dobbs LG, Johnson MD: Alveolar epithelial 
transport in the adult lung. Respir Physiol 
Neurobiol 2007; 159: 283–300. 
 3 Mason RJ: Biology of alveolar type II cells. 
Respirology 2006; 11(suppl): S12–S15. 
 4 Herzog EL, Brody AR, Colby TV, Mason R, 
Williams MC: Knowns and unknowns of the 
alveolus. Proc Am Thorac Soc 2008; 5: 778–
782. 
 5 Selman M, Pardo A: Role of epithelial cells in 
idiopathic pulmonary fibrosis: from inno-
cent targets to serial killers. Proc Am Thorac 
Soc 2006; 3: 364–372. 
 6 Maher TM, Wells AU, Laurent GJ: Idiopath-
ic pulmonary fibrosis: multiple causes and 
multiple mechanisms? Eur Respir J 2007; 30: 
 835–839. 
 7 Thannickal VJ, Horowitz JC: Evolving con-
cepts of apoptosis in idiopathic pulmonary 
fibrosis. Proc Am Thorac Soc 2006; 3: 350–
356. 
 8 Chilosi M, Poletti V, Murer B, Lestani M, 
Cancellieri A, et al: Abnormal re-epithelial-
ization and lung remodeling in idiopathic 
pulmonary fibrosis: the role of deltaN-p63. 
Lab Invest 2002; 82: 1335–1345. 
 9 Kasper M, Haroske G: Alterations in the al-
veolar epithelium after injury leading to pul-
monary fibrosis. Histol Histopathol 1996; 11: 
 463–483. 
 10 Qunn L, Takemura T, Ikushima S, Ando T, 
Yanagawa T, et al: Hyperplastic epithelial 
foci in honeycomb lesions in idiopathic pul-
monary fibrosis. Virchows Arch 2002; 441: 
 271–278. 
 11 Aubry MC, Myers JL, Douglas WW, Tazelaar 
HD, Washington Stephens TL, et al: Primary 
pulmonary carcinoma in patients with idio-
pathic pulmonary fibrosis. Mayo Clin Proc 
2002; 77: 763–770. 
 12 Nagai A, Chiyotani A, Nakadate T, Konno K: 
Lung cancer in patients with idiopathic pul-
monary fibrosis. Tohoku J Exp Med 1992; 
 167: 231–237. 
 13 Hironaka M, Fukayama M: Pulmonary fi-
brosis and lung carcinoma: a comparative 
study of metaplastic epithelia in honey-
combed areas of usual interstitial pneumo-
nia with or without lung carcinoma. Pathol 
Int 1999; 49: 1060–1066. 
 14 Artinian V, Kvale PA: Cancer and interstitial 
lung disease. Curr Opin Pulm Med 2004; 10: 
 425–434. 
 15 Baumgartner KB, Samet JM, Stidley CA, 
Colby TV, Waldron JA: Cigarette smoking: a 
risk factor for idiopathic pulmonary fibrosis. 
Am J Respir Crit Care Med 1997; 155: 242–
248. 
 16 Bai JW, Deng WW, Wu HC: The effect of 
montelukast on airway remodeling and the 
expression of interleukins and transforming 
growth factor-beta2 mRNA (in Chinese). 
Zhonghua Jie He He Hu Xi Za Zhi 2004; 27: 
 524–528. 
 17 Hubbard R, Venn A, Lewis S, Britton J: Lung 
cancer and cryptogenic fibrosing alveolitis: a 
population-based cohort study. Am J Respir 
Crit Care Med 2000; 161: 5–8. 
 18 Park J, Kim DS, Shim TS, Lim CM, Koh Y, et 
al: Lung cancer in patients with idiopathic 
pulmonary fibrosis. Eur Respir J 2001; 17: 
 1216–1219. 
 19 Kawasaki H, Nagai K, Yokose T, Yoshida
J, Nishimura M, et al: Clinicopathological 
characteristics of surgically resected lung 
cancer associated with idiopathic pulmo-
nary fibrosis. J Surg Oncol 2001; 76: 53–57. 
 20 Haddad R, Massaro D: Idiopathic diffuse in-
terstitial pulmonary fibrosis (fibrosing al-
veolitis), atypical epithelial proliferation and 
lung cancer. Am J Med 1968; 45: 211–219. 
 21 Pan LH, Yamauchi K, Uzuki M, Nakanishi T, 
Takigawa M, et al: Type II alveolar epithelial 
cells and interstitial fibroblasts express con-
nective tissue growth factor in IPF. Eur 
Respir J 2001; 17: 1220–1227. 
 22 Brody AR, Craighead JE: Interstitial associa-
tions of cells lining air spaces in human pul-
monary fibrosis. Virchows Arch A Pathol 
Anat Histol 1976; 372: 39–49. 
 23 Coalson JJ: The ultrastructure of human fi-
brosing alveolitis. Virchows Arch A Pathol 
Anat Histopathol 1982; 395: 181–199. 
 24 Corrin B, Dewar A: Pathogenesis of idio-
pathic interstitial pulmonary fibrosis. Ultra-
struct Pathol 1996; 20: 369–371. 
 Königshoff
 
 Respiration 2011;81:353–358 358
 25 Fukuda Y, Ferrans VJ, Schoenberger CI, 
Rennard SI, Crystal RG: Patterns of pulmo-
nary structural remodeling after experimen-
tal paraquat toxicity: the morphogenesis of 
intraalveolar fibrosis. Am J Pathol 1985; 118: 
 452–475. 
 26 Adamson IY, Young L, Bowden DH: Rela-
tionship of alveolar epithelial injury and re-
pair to the induction of pulmonary fibrosis. 
Am J Pathol 1988; 130: 377–383. 
 27 Königshoff M, Kramer M, Balsara N, Wil-
helm J, Amarie OV, et al: WNT1-inducible 
signaling protein-1 mediates pulmonary fi-
brosis in mice and is upregulated in humans 
with idiopathic pulmonary fibrosis. J Clin 
Invest 2009; 119: 772–787. 
 28 Willis BC, Liebler JM, Luby-Phelps K, Nich-
olson AG, Crandall ED, et al: Induction of 
epithelial-mesenchymal transition in alveo-
lar epithelial cells by transforming growth 
factor-beta1:potential role in idiopathic pul-
monary fibrosis. Am J Pathol 2005; 166: 1321–
1332. 
 29 Kim KK, Kugler MC, Wolters PJ, Robillard 
L, Galvez MG, et al: Alveolar epithelial cell 
mesenchymal transition develops in vivo 
during pulmonary fibrosis and is regulated 
by the extracellular matrix. Proc Natl Acad 
Sci USA 2006; 103: 13180–13185. 
 30 Lee JM, Dedhar S, Kalluri R, Thompson EW: 
The epithelial-mesenchymal transition: new 
insights in signaling, development, and dis-
ease. J Cell Biol 2006; 172: 973–981. 
 31 Thiery JP: Epithelial-mesenchymal transi-
tions in development and pathologies. Curr 
Opin Cell Biol 2003; 15: 740–746. 
 32 Zavadil J, Bottinger EP: TGF-beta and epi-
thelial-to-mesenchymal transitions. Onco-
gene 2005; 24: 5764–5774. 
 33 Huber MA, Kraut N, Beug H: Molecular 
 requirements for epithelial-mesenchymal 
transition during tumor progression. Curr 
Opin Cell Biol 2005; 17: 548–558. 
 34 Dasari V, Gallup M, Lemjabbar H, Maltseva 
I, McNamara N: Epithelial-mesenchymal 
transition in lung cancer: is tobacco the 
‘smoking gun’? Am J Respir Cell Mol Biol 
2006; 35: 3–9. 
 35 Willis BC, Borok Z: TGF-beta-induced EMT: 
mechanisms and implications for fibrotic 
lung disease. Am J Physiol Lung Cell Mol 
Physiol 2007; 293:L525–L534. 
 36 Willis BC, duBois RM, Borok Z: Epithelial 
origin of myofibroblasts during fibrosis in the 
lung. Proc Am Thorac Soc 2006; 3: 377–382. 
 37 Pennison M, Pasche B: Targeting transform-
ing growth factor-beta signaling. Curr Opin 
Oncol 2007; 19: 579–585. 
 38 Kasai H, Allen JT, Mason RM, Kamimura T, 
Zhang Z: TGF-beta1 induces human alveo-
lar epithelial to mesenchymal cell transition 
(EMT). Respir Res 2005; 6: 56. 
 39 Jayachandran A, Königshoff M, Yu H, 
Rupniewska E, Hecker M, et al: SNAI tran-
scription factors mediate epithelial-mesen-
chymal transition in lung fibrosis. Thorax 
2009; 64: 1053–1061. 
 40 Hu J, Van den Steen PE, Sang QX, Opdenak-
ker G: Matrix metalloproteinase inhibitors as 
therapy for inflammatory and vascular dis-
eases. Nat Rev Drug Discov 2007; 6: 480–498. 
 41 Radisky DC, Przybylo JA: Matrix metallo-
proteinase-induced fibrosis and malignancy 
in breast and lung. Proc Am Thorac Soc 
2008; 5: 316–322. 
 42 Rosas IO, Richards TJ, Konishi K, Zhang Y, 
Gibson K, et al: MMP1 and MMP7 as poten-
tial peripheral blood biomarkers in idiopath-
ic pulmonary fibrosis. PLoS Med 2008; 5:e93. 
 43 Huang CL, Liu D, Ishikawa S, Nakashima T, 
Nakashima N, et al: Wnt1 overexpression 
promotes tumour progression in non-small 
cell lung cancer. Eur J Cancer 2008; 44: 2680–
2688. 
 44 Ha HY, Moon HB, Nam MS, Lee JW, Ryoo 
ZY, et al: Overexpression of membrane-type 
matrix metalloproteinase-1 gene induces 
mammary gland abnormalities and adeno-
carcinoma in transgenic mice. Cancer Res 
2001; 61: 984–990. 
 45 Sternlicht MD, Lochter A, Sympson CJ, Huey 
B, Rougier JP, et al: The stromal  proteinase 
MMP3/stromelysin-1 promotes mammary 
carcinogenesis. Cell 1999; 98: 137–146. 
 46 Sato M, Shames DS, Gazdar AF, Minna JD: 
A translational view of the molecular patho-
genesis of lung cancer. J Thorac Oncol 2007; 
 2: 327–343. 
 47 Kuwano K, Kunitake R, Kawasaki M, Nomo-
to Y, Hagimoto N, et al: P21Waf1/Cip1/Sdi1 
and p53 expression in association with DNA 
strand breaks in idiopathic pulmonary fi-
brosis. Am J Respir Crit Care Med 1996; 154: 
 477–483. 
 48 Kawasaki H, Ogura T, Yokose T, Nagai K, 
Nishiwaki Y, et al: p53 gene alteration in 
atypical epithelial lesions and carcinoma in 
patients with idiopathic pulmonary fibrosis. 
Hum Pathol 2001; 32: 1043–1049. 
 49 Plataki M, Koutsopoulos AV, Darivianaki K, 
Delides G, Siafakas NM, et al: Expression of 
apoptotic and antiapoptotic markers in epi-
thelial cells in idiopathic pulmonary fibro-
sis. Chest 2005; 127: 266–274. 
 50 Selman M, Pardo A, Kaminski N: Idiopathic 
pulmonary fibrosis: aberrant recapitulation 
of developmental programs? PLoS Med 
2008; 5:e62. 
 51 Königshoff M, Eickelberg O: WNT signaling 
in lung disease: a failure or a regeneration sig-
nal? Am J Respir Cell Mol Biol 2010; 42: 21–31. 
 52 Königshoff M, Balsara N, Pfaff EM, Kramer 
M, Chrobak I, et al: Functional Wnt signal-
ing is increased in idiopathic pulmonary fi-
brosis. PLoS One 2008; 3:e2142. 
 53 Chilosi M, Poletti V, Zamo A, Lestani M, 
Montagna L, et al: Aberrant Wnt/beta-
catenin pathway activation in idiopathic 
pulmonary fibrosis. Am J Pathol 2003; 162: 
 1495–1502. 
 54 Moon RT, Kohn AD, De Ferrari GV, Kaykas 
A: WNT and beta-catenin signalling: diseas-
es and therapies. Nat Rev Genet 2004; 5: 691–
701. 
 55 Liu L, Carron B, Yee HT, Yie TA, Hajjou M, 
et al: Wnt pathway in pulmonary fibrosis in 
the bleomycin mouse model. J Environ 
Pathol Toxicol Oncol 2009; 28: 99–108. 
 56 Flozak AS, Lam AP, Russell S, Jain M, Peled 
ON, et al: Beta-catenin/T-cell factor signal-
ing is activated during lung injury and pro-
motes the survival and migration of alveolar 
epithelial cells. J Biol Chem 2010; 285: 3157–
3167. 
 57 Berschneider B, Königshoff M: WNT1 in-
ducible signaling pathway protein 1 (WISP1): 
a novel mediator linking development and 
disease. Int J Biochem Cell Biol. 2011; 43: 
 306–309. 
 58 Kim K, Lu Z, Hay ED: Direct evidence for a 
role of beta-catenin/LEF-1 signaling path-
way in induction of EMT. Cell Biol Int 2002; 
 26: 463–476. 
 59 Kato N, Shimmura S, Kawakita T, Miyashita 
H, Ogawa Y, et al: Beta-catenin activation 
and epithelial-mesenchymal transition in 
the pathogenesis of pterygium. Invest Oph-
thalmol Vis Sci 2007; 48: 1511–1517. 
 60 Dissanayake SK, Wade MS, Johnson
CE, O’Connell M P, Leotlela PD, et al: The 
WNT5A/ PKC pathway mediates motility in 
melanoma cells via the inhibition of metas-
tasis suppressors, and initiation of an epithe-
lial to mesenchymal transition. J Biol Chem. 
2007; 282: 17259–17271. 
 61 Chen PP, Li WJ, Wang Y, Zhao S, Li DY, et al: 
Expression of Cyr61, CTGF, and WISP-1 
correlates with clinical features of lung can-
cer. PLoS One 2007; 2:e534. 
 62 Margalit O, Eisenbach L, Amariglio N, Ka-
minski N, Harmelin A, et al: Overexpression 
of a set of genes, including WISP-1, common 
to pulmonary metastases of both mouse 
D122 Lewis lung carcinoma and B16-F10.9 
melanoma cell lines. Br J Cancer 2003; 89: 
 314–319. 
 63 Soon LL, Yie TA, Shvarts A, Levine AJ, Su F, 
et al: Overexpression of WISP-1 down-regu-
lated motility and invasion of lung cancer 
cells through inhibition of Rac activation. J 
Biol Chem 2003; 278: 11465–11470. 
 64 Mazieres J, He B, You L, Xu Z, Jablons DM: 
Wnt signaling in lung cancer. Cancer Lett 
2005; 222: 1–10. 
 65 Uematsu K, He B, You L, Xu Z, McCormick 
F, et al: Activation of the Wnt pathway in non 
small cell lung cancer: evidence of dishev-
elled overexpression. Oncogene 2003;  22: 
 7218–7221. 
 66 Kim J, You L, Xu Z, Kuchenbecker K, Raz D, 
et al: Wnt inhibitory factor inhibits lung can-
cer cell growth. J Thorac Cardiovasc Surg 
2007; 133: 733–737. 
